drugset

drugset / Trial / NCT03463408

Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma

NCT03463408 ↗

Phase 0 Active not recruiting 14 enrolled University of Rochester

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma

Timeline

Start: 2018-07-17
Primary completion: 2026-08-01
Completion: 2026-08-01

Publications

Vatner R, James CD, Sathiaseelan V, Bondra KM, Kalapurakal JA, Houghton PJ. Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges. Pediatr Blood Cancer. 2021 May;68 Suppl 2:e28439. doi: 10.1002/pbc.28439. Epub 2020 Aug 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ipilimumab	Monoclonal antibody	1 mg/kg	—
Subject	Nivolumab	Monoclonal antibody	240 mg	—

Indications